Table 1 Recruited patients
From: Bronchoalveolar lavage cytological alveolar damage in patients with severe pneumonia
Group | Patients with community-acquired pneumonia | Patients with hospital-acquired pneumonia (n = 57) | |
|---|---|---|---|
With pneumonia | With pneumonia | Without pneumoniac | |
Patients, n (%) | 15 | 39 (68.4%) | 18 (31.6%) |
Age, years (mean ± SD) | 69.0 ± 17.4 | 65.3 ± 15.9 | 62.6 ± 19.7 |
Male gender n (%) | 8 (53.3%) | 26 (66.7%) | 9 (50%) |
Co-morbidities, n | 8 | 25 | 10 |
Cardiac failure | 0 | 8 | 2 |
Neoplastic disease | 2 | 5 | 0 |
AIDS | 2 | 2 | 1 |
Chronic respiratory failure | 2 | 2 | 1 |
Cirrhosis | 2 | 8 | 6 |
Ventilation, days before bronchoalveolar lavagea (median (IQR)) | 1 (0–2) | 8 (3–15) | 3 (0–10.5) |
Length of stay in ICU (median (IQR)) | 4.5 (1.0–15.7) | 18 (10.7–34.0) | 18 (7.5–30.2) |
Mortality, n (%) | 12 (80%) | 21 (53.8%) | 10 (55.6%) |
SAPS II at admission (mean ± SD) | 74.45 ± 21.50 | 64.36 ± 20.60 | 60.83 ± 21.41 |
SAPS II at inclusion (mean ± SD) | - | 53.0 ± 19.4 | 66.0 ± 26.1 |
Vasoactive drugs (yes/no) | 12/3 | 29/10 | 10/8 |
Number of failing organsb (median (IQR)) | 2 (2–3) | 3 (1–3) | 2 (1–3) |
None | 0 | 7 | 2 |
1 | 2 | 6 | 5 |
2 | 8 | 6 | 3 |
3 | 4 | 11 | 5 |
4 | 1 | 7 | 1 |
5 | 0 | 1 | 2 |
6 | 0 | 1 | 0 |
Thoracic radiograph | |||
Bilateral opacities, n (%) | 7 (46.7%) | 20 (51.3%) | 11 (61.1%) |
Multilobar involvement, n (%) | 11 (73.3%) | 21 (53.8%) | 13 (72.2%) |
Clinical variables (mean ± SD) | |||
MAP, mmHg | 68.11 ± 19.27 | 64.6 ± 16.6 | 61.55 ± 19.94 |
GCS before sedation | 11.2 ± 5.0 | 9.85 ± 5.24 | 11.8 ± 4.9 |
GCS > 9 | 10 | 22 | 13 |
PaO2/FiO2, mmHg | 177.91 ± 88.43 | 190.0 ± 63.3 | 195.27 ± 86.20 |
Creatinine, µmol/l | 162.4 ± 66.4 | 198 ± 196 | 162 ± 122.2 |